Targeting alphavbeta3 integrin: design and applications of mono- and multifunctional RGD-based peptides and semipeptides
- PMID: 20166941
- DOI: 10.2174/092986710790936301
Targeting alphavbeta3 integrin: design and applications of mono- and multifunctional RGD-based peptides and semipeptides
Abstract
The outstanding physio-pathological role played by integrin receptors in living subjects motivates the enormous interest shown by scientists worldwide for this topic. More than twenty years of research has spanned across the structural and functional elucidation of these proteins and over their antagonism-based biomedical applications. The proof-of concept stage, aimed at identifying potent inhibitors, covered a decade of studies, and paved the way for a more advanced era of research where these antagonist molecules were thrown into the deep end of applicative studies. This review intends to summarize the major efforts conducted thus far and focuses on the design, synthesis and biomedical applications of cyclic RGD-containing alpha(v)beta(3) integrin antagonists, in both their small and macromolecular formats. In particular, Chapters 1 and 2 offer a comprehensive outlook on the rational basis for the design of integrin inhibitors, Chapter 3 chronicles the biological and medical applications of monofunctional RGD integrin ligands both in their monomeric and multimeric asset, and Chapter 4 illustrates the potential of RGD-based multifunctional systems in molecular medicine.
Similar articles
-
Ligands for mapping alphavbeta3-integrin expression in vivo.Acc Chem Res. 2009 Jul 21;42(7):969-80. doi: 10.1021/ar800243b. Acc Chem Res. 2009. PMID: 19489579
-
Design and synthesis of novel dual-cyclic RGD peptides for αvβ3 integrin targeting.Bioorg Med Chem Lett. 2019 Apr 1;29(7):896-900. doi: 10.1016/j.bmcl.2019.01.043. Epub 2019 Feb 1. Bioorg Med Chem Lett. 2019. PMID: 30732943
-
New potent and selective αvβ3 integrin ligands: Macrocyclic peptides containing RGD motif synthesized by sortase A-mediated ligation.Bioorg Med Chem Lett. 2017 May 1;27(9):1911-1913. doi: 10.1016/j.bmcl.2017.03.035. Epub 2017 Mar 18. Bioorg Med Chem Lett. 2017. PMID: 28351594
-
RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature.Drug Resist Updat. 2005 Dec;8(6):381-402. doi: 10.1016/j.drup.2005.10.002. Epub 2005 Nov 23. Drug Resist Updat. 2005. PMID: 16309948 Review.
-
Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers.Anticancer Agents Med Chem. 2007 Sep;7(5):552-8. doi: 10.2174/187152007781668706. Anticancer Agents Med Chem. 2007. PMID: 17896915 Review.
Cited by
-
Cyclic RGD Peptides Incorporating Cycloalkanes: Synthesis and Evaluation as PET Radiotracers for Tumor Imaging.ACS Med Chem Lett. 2014 Jul 10;5(9):979-82. doi: 10.1021/ml500135t. eCollection 2014 Sep 11. ACS Med Chem Lett. 2014. PMID: 25221652 Free PMC article.
-
Synthesis, Characterization, and Biological Evaluation of a Dual-Action Ligand Targeting αvβ3 Integrin and VEGF Receptors.ChemistryOpen. 2015 Oct;4(5):633-41. doi: 10.1002/open.201500062. Epub 2015 Jul 2. ChemistryOpen. 2015. PMID: 26491644 Free PMC article.
-
Evaluation of two novel ⁶⁴Cu-labeled RGD peptide radiotracers for enhanced PET imaging of tumor integrin αvβ₃.Eur J Nucl Med Mol Imaging. 2015 Nov;42(12):1859-68. doi: 10.1007/s00259-015-3085-7. Epub 2015 May 28. Eur J Nucl Med Mol Imaging. 2015. PMID: 26016906 Free PMC article.
-
Peptide-Based Strategies for Targeted Tumor Treatment and Imaging.Pharmaceutics. 2021 Apr 2;13(4):481. doi: 10.3390/pharmaceutics13040481. Pharmaceutics. 2021. PMID: 33918106 Free PMC article. Review.
-
RGDfK-functionalized gold nanorods bind only to activated platelets.J Biomed Mater Res A. 2017 Jan;105(1):209-217. doi: 10.1002/jbm.a.35902. Epub 2016 Oct 11. J Biomed Mater Res A. 2017. PMID: 27648522 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources